Zentalis repurchases 7.5M shares from Matrix at $1.33 each; director resigns

Zentalis Pharmaceuticals, Inc.

Repurchased 7,500,000 shares from Matrix Capital Master Fund at $1.33/share, a 5% discount to the Dec 12 close of $1.40.
Repurchase closed on December 15, 2025; funded by existing cash, with no material impact on projected cash runway into late 2027.
Director Karan Takhar (Matrix Capital) resigned immediately, reducing board size from 7 to 6; resignation not due to any disagreement.
Matrix's sale is part of its previously announced 2024 plan to wind down its family of funds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.